Exenatide Twice-Daily vs Once-Weekly: Clinical Comparison for Type 2 Diabetes
Exenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenience — advancing toward the weekly injection paradigm for GLP-1 drugs.
Quick Facts
What This Study Found
Exenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenience — advancing toward the weekly injection paradigm for GLP-1 drugs.
Key Numbers
How They Did This
research study.
Why This Research Matters
Relevant for peptide research.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
Trust & Context
- Key Stat:
- Key finding Exenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenienc
- Evidence Grade:
- emerging evidence.
- Study Age:
- Published in 2011.
- Original Title:
- Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
- Published In:
- Postgraduate medicine, 123(5), 228-38 (2011)
- Authors:
- Aroda, Vanita R(4), DeYoung, Mary Beth
- Database ID:
- RPEP-01734
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Exenatide Twice-Daily vs Once-Weekly: Clinical Comparison for Type 2 Diabetes
What was found?
Exenatide once-weekly (long-acting release) showed superior HbA1c reduction and comparable weight loss to twice-daily with improved patient convenience — advancing toward the weekly injection paradigm for GLP-1 drugs.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01734APA
Aroda, Vanita R; DeYoung, Mary Beth. (2011). Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.. Postgraduate medicine, 123(5), 228-38. https://doi.org/10.3810/pgm.2011.09.2479
MLA
Aroda, Vanita R, et al. "Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.." Postgraduate medicine, 2011. https://doi.org/10.3810/pgm.2011.09.2479
RethinkPeptides
RethinkPeptides Research Database. "Clinical implications of exenatide as a twice-daily or once-..." RPEP-01734. Retrieved from https://rethinkpeptides.com/research/aroda-2011-clinical-implications-of-exenatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.